Empagliflozin + metformin

Trade Name: 
Synjardy
Manufacturer/Distributor: 
Boehringer Ingelheim Canada
Classification: 
Oral blood glucose lowering agents
ATC Class: 
A10BD20 - metformin and empagliflozin
Status: 
active
Notice of Compliance (yyyy/mm/dd): 
2016/08/03
Date Marketed in Canada (yyyy/mm/dd): 
2017/09/18
Presentation: 
Tablet: 5 mg empagliflozin + 500 mg metformin. DIN: 02456575
Tablet: 5 mg empagliflozin + 850 mg metformin. DIN: 02456583
Tablet: 5 mg empagliflozin + 1000 mg metformin. DIN: 02456591
Tablet: 12.5 mg empagliflozin + 500 mg metformin. DIN: 02456605
Tablet: 12.5 mg empagliflozin + 850 mg metformin. DIN: 02456613
Tablet: 12.5 mg empagliflozin + 1000 mg metformin. DIN: 02456621
Comments: 
For use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes inadequately controlled with metformin OR a sulfonylurea in combination with metformin OR pioglitazone in combination with metformin OR insulin in combination with metformin. It cal also be used in patients already being treated and achieving glycemic control with metformin and empagliflozin as separate tablets OR a sulfonylurea in combination with metformin and empagliflozin as separate tablets OR pioglitazone in combination with metformin and empagliflozin as separate tablets OR insulin in combination with metformin and empagliflozin as separate tablets.